This article is more than 5 years old. Information may no longer be current.
Cardiology Today’s top news from October
Click Here to Manage Email Alerts
Cardiology Today compiled a list of the most-read stories posted to Healio.com/Cardiology in October. This month, our readers were interested in racial differences in incident hypertension, a new protocol to determine risk from chest pain, a new indication for rivaroxaban (Xarelto, Janssen/Bayer), hypertension risk in patients with atrial fibrillation and more.
Racial differences in incident hypertension driven by diet, education level
Racial differences in men and women regarding incident hypertension were related to the dietary ratio of sodium to potassium, Southern dietary pattern and education level, according to a study published in JAMA.
Accelerated diagnostic protocol determines risk in patients with chest pain
An accelerated diagnostic protocol to identify patients who present to the ED with chest pain as low risk and for early discharge without further testing increased the identification of MI and decreased hospitalizations, according to a study published in Circulation: Cardiovascular Quality and Outcomes.
Rivaroxaban approved to prevent CV events in CAD, PAD
Janssen announced that the FDA has approved its factor Xa inhibitor rivaroxaban for reduction of risk for major adverse CV events in patients with chronic CAD or peripheral artery disease.
New BP threshold identifies risk in patients with AF, hypertension
Patients with atrial fibrillation who also have hypertension as defined by the 2017 guideline had increased risk for major CV events, leading researchers for a new study to state that “the new BP threshold is beneficial for timely diagnosis and intervention.”
Agent reduces Lp(a) levels in phase 2 study
Akcea Therapeutics Inc. announced that a phase 2 study of AKCEA-APO(a)-LRX showed that the drug was tolerable and lowered lipoprotein(a) levels in patients with CVD.
Latest CV outcomes trials suggest safety, benefit for newer diabetes therapies
BOSTON — Results from key CV outcomes trials presented and soon to be presented in 2018 continue to demonstrate CV safety for several new antidiabetes therapies, and the results are now influencing clinical guidelines, according to a presenter at the Cardiometabolic Health Congress.
Alcohol consumption may prompt adverse cardiac remodeling
Elevated alcohol consumption predicted several parameters of adverse cardiac remodeling after 20 years of follow-up, researchers reported.
Sleep duration related to stroke risk, varies by race
Black men who sleep for a short amount of time had a decreased risk for incident stroke, and white men with longer sleep duration had an increased risk for incident stroke, according to a study published in Neurology.
Hookah smoking stiffens arteries similar to cigarettes
Hookah smoking may cause an acute increase in arterial stiffness in young adults that is similar to the effects of smoking cigarettes, according to a study published in The American Journal of Cardiology.
LVAD now approved as destination therapy
Abbott announced that its newest-generation left ventricular assist device has been approved by the FDA for implantation in patients with advanced HF ineligible for a heart transplant.